Search Results

Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it has entered into an agreement with the University of Miami (the “University”) for the exclusive worldwide license of the University’s intellectual property related to photodynamic antimicrobial therapy (“PDAT”) for treating bacterial, fungal, and parasitic (acanthamoeba) infections of the eye.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.

Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.

Prelude Corporation today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.

Agendia®, Inc., announced it will share new data from the ongoing prospective, observational FLEX Trial in two poster presentations at the 41st Annual Miami Breast Cancer Conference, taking place March 7 – 10th, 2024.

Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) today announced it has entered into an exclusive licensing agreement with the University of Miami (or the “University”) for its intellectual property portfolio entitled “Long Acting Local Analgesic” and “Long Acting Local Analgesic Mechanisms.”

Siemens Healthineers and UHealth - University of Miami Health System announced a Value Partnership1 agreement.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Boston-MA- Gel4Med, an innovative biomaterials company, is thrilled to announce a three-year $1.75M collaborative grant awarded by the Congressionally Directed Medical Research Programs (CDMRP)/Department of Defense (DoD) to evaluate new therapeutic approaches with the potential to revolutionize the treatment landscape in spinal cord injury (SCI).